Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ivonescimab combined with cadonilimab or ipilimumab in advanced renal cell carcinoma
CTR20263290Phase 2Active
- Sponsor
- CTTQ-Akeso
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab, cadonilimab, ipilimumab in renal cell carcinoma (RCC), sponsored by CTTQ-Akeso. Started Sep 2026; status: active.
02
Drugs
ivonescimabcadonilimabipilimumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on CTR20263290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263290.